Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Consorzio Mario Negri Sud
- Target Recruit Count
- 365
- Registration Number
- NCT01645124
- Locations
- 🇮🇹
IRCCS Ospedale Casa Sollievo della Sofferenza di San Giovanni Rotondo, San Giovanni Rotondo, Foggia, Italy
🇮🇹IRCCS Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Potenza, Italy
🇮🇹Università di Padova, Padova, Italy
Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 38
- Registration Number
- NCT01531387
- Locations
- 🇯🇲
Tropical Medicine Research Institute, University of the West Indies (UWI), Mona, Kingston, Jamaica
🇧🇷Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Centro, Rio de Janeiro, Brazil
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
- Conditions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Registration Number
- NCT01521299
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 39
- Registration Number
- NCT01506544
- Locations
- 🇺🇸
Children's Memorial Hospital (Northwestern University), Chicago, Illinois, United States
🇺🇸UT Southwestern University Hospital, Dallas, Texas, United States
🇺🇸Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 159
- Registration Number
- NCT01425307
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 28
- Registration Number
- NCT01389024
- Locations
- 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Thomas Stauffer Larsen
- Target Recruit Count
- 202
- Registration Number
- NCT01387763
- Locations
- 🇩🇰
Dept of Hematology, Aalborg hospital, Aalborg, Denmark
🇩🇰Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Dept of Hematology, Herlev Hospital, Herlev, Denmark
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
- Conditions
- Interventions
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Ronald Hoffman
- Target Recruit Count
- 168
- Registration Number
- NCT01259856
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇮🇹University Of Florence, Florence, Italy
🇺🇸Stanford University School of Medicine, Stanford, California, United States
Hydroxyurea in Primary Progressive Multiple Sclerosis
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- S. Andrea Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT01103583
- Locations
- 🇮🇹
Centre for Experimental Neurological Therapies (CENTERS), S.Andrea Hospital, Rome, Italy
🇮🇹Centre for Experimental Neurological Therapies (CENTERS), Tor Vergata University Hospital, Rome, Italy
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Registration Number
- NCT01065038
- Locations
- 🇩🇪
Center Munich, Munich, Bavaria, Germany
🇨🇿Center Olomouc, Olomouc, Czech Republic
🇵🇱Center Gdansk, Gdansk, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.